nach oben

American Journal of Cardiovascular Drugs

Erschienen in:

01.06.2012 | Review Article

Therapeutic Potential of Terminalia Arjuna in Cardiovascular Disorders

verfasst von: Dr Subir K. Maulik, Kewal K. Talwar

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The bark of the tree Terminalia arjuna (Roxb.) is widely used in Indian medicine (Ayurveda) for various cardiovascular ailments. The bark has been reported to contain several bioactive compounds. Many experimental studies have reported its antioxidant, anti-ischemic, antihypertensive, and antihypertrophic effects, which have relevance to its therapeutic potential in cardiovascular diseases in humans. Several clinical studies have reported its efficacy mostly in patients with ischemic heart disease, hypertension, and heart failure. However, a major shortcoming in all these experimental and clinical studies is the absence of phytochemical standardization of the extracts. In addition, many clinical studies are poor in terms of design and methods used for generating safety data. This review discusses how to address all these issues for a scientific validation of this medicinal plant.

Reddy KS, Satija A. The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India. Prog Cardiovasc Dis 2010; 53(1): 21–7PubMedCrossRef

Daviglus ML, Lloyd-Jones DM, Pirzada A. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. Am J Cardiovasc Drugs 2006; 6(2): 87–101PubMedCrossRef

Kirtikar KR, Basu BD. Terminalia arjuna. In: Kirtikar KR, Basu BD, editors. Indian medicinal plants. Volume II. 2nd ed. Allahabad: Lalit Mohan Basu Publications, 1935: 1023–8

Singh B, Singh VP, Pandey VB, et al. A new triterpene glycoside from Terminalia arjuna. Planta Medica 1995; 61: 576–7PubMedCrossRef

Kandil FE, Nassar MI. A tannin anticancer promoter from Terminalia arjuna. Phytochemistry 1998; 47: 1567–8PubMedCrossRef

Ali A, Abdullah ST, Hamid H, et al. Two new pentacyclic triterpenoid glycosides from the bark of Terminalia arjuna. Ind J Chem 2003; 42B: 2905–8

King FE, King TJ, Ross JM. The constituent of arjunoilc acid, a triterpene from Terminalia arjuna. J Chem Soc 1954; 3995–4003

Singh DV, Verma RK, Singh SC, et al. RP-LC determination of oleane derivatives in Terminalia arjuna. J Pharm Biomed Anal 2002; 28: 447–52PubMedCrossRef

Row LR, Murty PS, Rao GSRS, et al. Chemical examination of Terminalia species: Part XIII-Isolationa& structure determination of Arjunetin, from Terminalia arjuna. Ind J. Chem 1970; 8: 772–5

10.

Chopra RN, Chopra IC, Handa KL, et al. (editors). Indigenous drugs of India. Kolkata: U.N. Dhur and Sons, 1958; pp. 51–595

11.

Singh N, Kapur KK, Singh SP, et al. Mechanism of cardiovascular action of Terminalia arjuna. Planta Med 1982; 45(2): 102–4PubMedCrossRef

12.

Takahashi S, Tanaka H, Hano Y, et al. Hypotensive effects in rats of hydrophilic extract from Terminalia arjuna containing tannin-related compounds. Phytother Res 1997; 1: 424–7CrossRef

13.

Gauthaman K, Banerjee SK, Dinda AK, et al. Terminalia arjuna (Roxb.) protects rabbit heart against ischemic-reperfusion injury: role of antioxidant enzymes and heat shock protein. J Ethnopharmacol 2005; 96(3): 403–9PubMedCrossRef

14.

Dwivedi S, Somani PN, Chansouria JPN, et al. Cardioprotective effects of certain indigenous drugs in myocardial ischemia in rabbits. Indian J Exp Biol 1988; 26(12): 969–75PubMed

15.

Pawar RS, Bhutani KK. Effect of oleanane triterpenoids from Terminalia arjuna: a cardioprotective drug on the process of respiratory oxyburst. Phytomedicine 2005; 12(5): 391–3PubMedCrossRef

16.

Gauthaman K, Maulik M, Kumari R, et al. Effect of chronic treatment with bark of Terminalia arjuna: a study on the isolated ischemic-reperfused rat heart. J. Ethnopharmacol 2001; 75(2–3): 197–201PubMedCrossRef

17.

Sumitra M, Manikandan P, Kumar DA, et al. Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Mol Cell Biochem 2001; 224(1–2): 135–42PubMedCrossRef

18.

Khanna AK, Chander C, Kapoor NK. Terminalia arjuna: an Ayurvedic cardiotonic regulates lipid metabolism in hyperlipidemic rats. Phytother Res 1996; 10(8): 663–6CrossRef

19.

Subramaniam S, Ramachandran S, Uthrapathi S, et al. Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX- 407 induced hyperlipidemia. Indian J Exp Biol 2011; 49(4): 282–8

20.

Subramaniam S, Subramaniam R, Rajapandian S, et al. Anti-atherogenic activity of ethanolic fraction of Terminalia arjuna bark on hypercholesterolemic rabbits. Evid Based Complement Alternat Med 2011; 487–916

21.

Kumar S, Enjamoori R, Jaiswal A, et al. Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.). J Pharm Pharmacol 2009; 61(11): 1529–36PubMed

22.

Oberoi L, Akiyama T, Lee KH, et al. The aqueous extract, not organic extracts, of Terminalia arjuna bark exerts cardiotonic effect on adult ventricular myocytes. Phytomedicine 2011 Feb 15; 18(4): 259–6PubMedCrossRef

23.

Dwivedi S, Agarwal MP. Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary artery disease. J Assoc Phys India 1994; 42(4): 287–9

24.

Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian Heart J 1997; 49: 507–10PubMed

25.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302CrossRef

26.

Bharani A, Ganguli A, Mathur LK, et al. Efficacy of Terminalia arjuna in chronic stable angina: a double blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart J 2002; 54(2): 170–5PubMed

27.

Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32(6): 1657–64PubMedCrossRef

28.

Dwivedi S, Aggarwal A, Agarwal MP, et al. Role of Terminalia arjuna in ischaemic mitral regurgitation. Int J Cardiol 2005 Apr 28; 100(3): 507–8PubMedCrossRef

29.

Bharani A, Ahirwar LK, Jain N. Terminalia arjuna reverses impaired endothelial function in chronic smokers. Indian Heart J 2004; 6(2): 123–8

30.

Raitakari OT, Adams MR, McCredie RJ, et al. Oral vitamin C and endothelial function in smokers: short-term improvement, but no sustained beneficial effect. J Am Coll Cardiol 2000; 35(6): 1616–21PubMedCrossRef

31.

Neunteufl T, Priglinger U, Heher S, et al. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol 2000; 35(2): 277–83PubMedCrossRef

32.

Rao BCS, Singh RH, Tripathi K. Effect of Terminalia arjuna (W&A) on regression of LVH in hypertensives: a clinical study. J Res Ayurveda Sidhha 2001; XXII(3–4): 216–27

33.

Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54(5): 1084–91PubMedCrossRef

34.

Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995; 49: 191–9PubMedCrossRef

35.

Greenberg B, Borghi C, Perrone S. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan? Eur J Heart Fail 2003; 5(1): 13–21PubMedCrossRef

36.

Kontush A, Chapman MJ. Antiatherogenic small, dense HDL: guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3(3): 144–53PubMedCrossRef

37.

Gupta R, Singhal S, Goyle A, et al. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebocontrolled trial. J Assoc Physicians India 2001; 49: 231–5PubMed

38.

Malik N, Dhawan V, Bahl A, et al. Inhibitory effects of Terminalia arjuna on platelet activation in vitro in healthy subjects and patients with coronary artery disease. Platelets 2009; 20(3): 183–90PubMedCrossRef

39.

Sandhu JS, Shah B, Shenoy S, et al. Effects of Withania somnifera (Ashwagandha) and Terminalia arjuna (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults. Int J Ayurveda Res 2010 Jul; 1(3): 144–9PubMedCrossRef

40.

Jayakumar K. Bottlenecks in standardisation of traditional system of medicine. Res J Medicinal Plants 2011; 5(4): 443–7CrossRef

Titel: Therapeutic Potential of Terminalia Arjuna in Cardiovascular Disorders
verfasst von: Dr Subir K. Maulik
Kewal K. Talwar
Publikationsdatum: 01.06.2012
Verlag: Springer International Publishing
Erschienen in: American Journal of Cardiovascular Drugs / Ausgabe 3/2012
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI: https://doi.org/10.2165/11598990-000000000-00000

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Therapeutic Potential of Terminalia Arjuna in Cardiovascular Disorders

Abstract

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics

Prasugrel: A Guide to Its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in the US

Heart Rate-Lowering Efficacy and Respiratory Safety of Ivabradine in Patients with Obstructive Airway Disease

Epidemiology and Management of Hypertension in the Hispanic Population

Comparison of the Efficacy and Safety of Fixed-Dose Amlodipine/Losartan and Losartan in Hypertensive Patients Inadequately Controlled with Losartan

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie